NEWCASTLE, England--(BUSINESS WIRE)--Iksuda Therapeutics (Iksuda), the developer of class leading, clinically validated antibody drug ... where differentiation from tubulin and topoisomerase ...

You have full access to this article via your institution. There are several methods for removing MAPs from MTP to produce purified tubulin: using DEAE-Sephadex or phosphocellulose chromatography ...

An anti-IL1RAP ADC was generated from an antibody selected from Cantargia's unique library of IL1RAP-targeting antibodies and conjugated to a tubulin-targeting payload using ImmunoGen (now part of ...